The Uromigos
All Episodes
David Braun divides immune therapies into four groups and describes how novel treatments and targets work. Tom and Brian are both excited and, at times, sceptical.
Jul 19
37 min 31 sec
Escuche nuestro primer podcast sobre los aspectos más destacados de ASCO en cáncer de vejiga, riñón y próstata
Jul 11
36 min 33 sec
Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions
Jul 5
26 min 20 sec
Viktor Gruenwald, Boris Hadaschik and Gunhild Von Amsberg answer questions around GU cancer and German football
Jun 26
35 min 55 sec
Aditya Bagrodia describes three new drugs/studies in NMIBC.
Jun 21
33 min 56 sec
Silke Gillessen joins Tom and Brian, who give their opinion on the data and new 'Take Home Message' format.
Jun 10
52 min 47 sec
Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura battle through the sometimes ridiculous questions set by Tom and Brian.
Jun 7
30 min 48 sec
David McDermott discusses the adjuvant vs neoadjuvant immune therapy trial and its wider implications.
Jun 5
26 min 32 sec
Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node only 1st line UC patients. Tom describes the QOL data for EV pembro.
Jun 4
24 min 2 sec
Laurence Albiges discusses this circulating biomarker which may be predictive and prognostic.
Jun 3
18 min 8 sec
Toni Choueiri and Brian describe similarities and differences in the biomarker findings of these two trials. Debate about the value and future of this approach breaks out.
Jun 3
33 min 44 sec
Andrea Necchi gives us the lowdown of efficacy and toxicity of this combination.
Jun 2
20 min 43 sec
